Foscavir

(Foscarnet)

Phase 3Small molecule

CClinigen, Inc.

Foscavir is one of 10 small molecule programs targeting Cytomegalovirus Retinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cytomegalovirus RetinitisActive, not recruiting

Cytomegalovirus RetinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Cytomegalovirus Retinitis

#DrugCompanyPhaseTrials

Cytovene

EExela Pharma Sciences, LLC.

Phase 3

7 2

Leukine

Vistide

2 4

Viracept

AAgouron Pharmaceuticals

Phase 2

1 5

Foscavir

CClinigen, Inc.

Phase 3

1 6

Vitravene Preservative Free

Novartis

Phase 2

2 7

Retrovir

BBp Consulting, Inc

Preclinical

2 8

Benemid

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Zovirax

BBp Consulting, Inc

Preclinical

1 10

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cytomegalovirus Retinitis1 trial

Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 3·NCT00000134·279 enrolled

Cytomegalovirus (CMV) Infection1 trial

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Completed· Takeda logo

Takeda·Phase 3·NCT02931539·352 enrolled

Complication1 trial

Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)

Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 3·NCT00000136·234 enrolled

CMV Infection1 trial

CMV-CTL for the Treatment of CMV Infection After HSCT

Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT03004261·5 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 27, 1991

FOSCAVIR

NDA NDA020068

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Foscarnet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Foscarnet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Foscarnet. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020068). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Clinigen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CClinigen, Inc.

Foscavir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cytomegalovirus Retinitis1 trial

Cytomegalovirus (CMV) Infection1 trial

Complication1 trial

CMV Infection1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News